[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse OTC

Summary
SymbolOTC
Nameornithine carbamoyltransferase
Aliases OTCase; ornithine transcarbamylase; Ornithine carbamoyltransferase, mitochondrial
Chromosomal LocationXp21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Mitochondrion matrix.
Domain PF00185 Aspartate/ornithine carbamoyltransferase
PF02729 Aspartate/ornithine carbamoyltransferase
Function

-

> Gene Ontology
 
Biological Process GO:0000050 urea cycle
GO:0000052 citrulline metabolic process
GO:0001101 response to acid chemical
GO:0001889 liver development
GO:0006520 cellular amino acid metabolic process
GO:0006525 arginine metabolic process
GO:0006526 arginine biosynthetic process
GO:0006591 ornithine metabolic process
GO:0006593 ornithine catabolic process
GO:0007494 midgut development
GO:0007584 response to nutrient
GO:0008652 cellular amino acid biosynthetic process
GO:0009063 cellular amino acid catabolic process
GO:0009064 glutamine family amino acid metabolic process
GO:0009084 glutamine family amino acid biosynthetic process
GO:0009991 response to extracellular stimulus
GO:0010035 response to inorganic substance
GO:0010038 response to metal ion
GO:0010043 response to zinc ion
GO:0016053 organic acid biosynthetic process
GO:0016054 organic acid catabolic process
GO:0019240 citrulline biosynthetic process
GO:0019627 urea metabolic process
GO:0031667 response to nutrient levels
GO:0032868 response to insulin
GO:0033273 response to vitamin
GO:0042450 arginine biosynthetic process via ornithine
GO:0042493 response to drug
GO:0043434 response to peptide hormone
GO:0044282 small molecule catabolic process
GO:0044283 small molecule biosynthetic process
GO:0046394 carboxylic acid biosynthetic process
GO:0046395 carboxylic acid catabolic process
GO:0048565 digestive tract development
GO:0048732 gland development
GO:0051259 protein oligomerization
GO:0051260 protein homooligomerization
GO:0055081 anion homeostasis
GO:0055123 digestive system development
GO:0061008 hepaticobiliary system development
GO:0070206 protein trimerization
GO:0070207 protein homotrimerization
GO:0070781 response to biotin
GO:0071941 nitrogen cycle metabolic process
GO:0097272 ammonia homeostasis
GO:1901565 organonitrogen compound catabolic process
GO:1901605 alpha-amino acid metabolic process
GO:1901607 alpha-amino acid biosynthetic process
GO:1901652 response to peptide
GO:1990267 response to transition metal nanoparticle
Molecular Function GO:0004585 ornithine carbamoyltransferase activity
GO:0005543 phospholipid binding
GO:0016597 amino acid binding
GO:0016741 transferase activity, transferring one-carbon groups
GO:0016743 carboxyl- or carbamoyltransferase activity
GO:0031406 carboxylic acid binding
GO:0042301 phosphate ion binding
GO:0043168 anion binding
Cellular Component GO:0005743 mitochondrial inner membrane
GO:0005759 mitochondrial matrix
> KEGG and Reactome Pathway
 
KEGG hsa01100 Metabolic pathways
hsa01230 Biosynthesis of amino acids
Reactome R-HSA-1430728: Metabolism
R-HSA-71291: Metabolism of amino acids and derivatives
R-HSA-351202: Metabolism of polyamines
R-HSA-70635: Urea cycle
Summary
SymbolOTC
Nameornithine carbamoyltransferase
Aliases OTCase; ornithine transcarbamylase; Ornithine carbamoyltransferase, mitochondrial
Chromosomal LocationXp21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between OTC and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolOTC
Nameornithine carbamoyltransferase
Aliases OTCase; ornithine transcarbamylase; Ornithine carbamoyltransferase, mitochondrial
Chromosomal LocationXp21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of OTC in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.66 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolOTC
Nameornithine carbamoyltransferase
Aliases OTCase; ornithine transcarbamylase; Ornithine carbamoyltransferase, mitochondrial
Chromosomal LocationXp21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of OTC in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.4940.293
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0430.957
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.8970.211
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.5180.533
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.6830.165
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.9540.495
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.4480.632
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.0160.564
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.3010.867
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2990.813
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7920.629
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.7090.0268
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of OTC in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277304.1-4.10.561
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolOTC
Nameornithine carbamoyltransferase
Aliases OTCase; ornithine transcarbamylase; Ornithine carbamoyltransferase, mitochondrial
Chromosomal LocationXp21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of OTC. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolOTC
Nameornithine carbamoyltransferase
Aliases OTCase; ornithine transcarbamylase; Ornithine carbamoyltransferase, mitochondrial
Chromosomal LocationXp21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of OTC. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by OTC.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolOTC
Nameornithine carbamoyltransferase
Aliases OTCase; ornithine transcarbamylase; Ornithine carbamoyltransferase, mitochondrial
Chromosomal LocationXp21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of OTC. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolOTC
Nameornithine carbamoyltransferase
Aliases OTCase; ornithine transcarbamylase; Ornithine carbamoyltransferase, mitochondrial
Chromosomal LocationXp21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of OTC expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolOTC
Nameornithine carbamoyltransferase
Aliases OTCase; ornithine transcarbamylase; Ornithine carbamoyltransferase, mitochondrial
Chromosomal LocationXp21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between OTC and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolOTC
Nameornithine carbamoyltransferase
Aliases OTCase; ornithine transcarbamylase; Ornithine carbamoyltransferase, mitochondrial
Chromosomal LocationXp21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting OTC collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting OTC.
ID Name Drug Type Targets #Targets
DB00129OrnithineSmall MoleculeARG1, ARG2, GATM, OAT, OAZ1, OAZ2, OAZ3, OTC, SLC25A15, SLC25A2, S ......14
DB00155L-CitrullineSmall MoleculeASS1, DDAH1, DDAH2, NOS1, NOS2, NOS3, OTC, PADI1, PADI2, PADI3, PA ......12
DB02011N-(Phosphonoacetyl)-L-OrnithineSmall MoleculeOTC1
DB04185NorvalineSmall MoleculeGATM, OTC2